Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 2, Pages e87309
Publisher
Public Library of Science (PLoS)
Online
2014-02-28
DOI
10.1371/journal.pone.0087309
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MoMA-LigPath: a web server to simulate protein–ligand unbinding
- (2013) Didier Devaurs et al. NUCLEIC ACIDS RESEARCH
- Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells
- (2012) Prasad Dandawate et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway
- (2012) Jianxin He et al. JOURNAL OF BIOSCIENCES
- A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line
- (2012) Inès Souissi et al. Molecular Cancer
- Structure activity relationship of plumbagin in BRCA1 related cancer cells
- (2012) Thasni K.A. et al. MOLECULAR CARCINOGENESIS
- Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design
- (2012) Hengmiao Cheng et al. ACS Medicinal Chemistry Letters
- Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
- (2011) S. J. Shuttleworth et al. CURRENT MEDICINAL CHEMISTRY
- Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review
- (2011) Naval Bajwa et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
- (2011) Roman A. Laskowski et al. Journal of Chemical Information and Modeling
- Synthesis and Biological Evaluation of Apogossypolone Derivatives as Pan-active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
- (2010) Jun Wei et al. JOURNAL OF MEDICINAL CHEMISTRY
- 5-Hydroxy-2-Methyl-1,4-Naphthoquinone, a Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization
- (2010) S. K. Sandur et al. MOLECULAR CANCER RESEARCH
- Plumbagin, Isolated from Plumbago zeylanica, Induces Cell Death through Apoptosis in Human Pancreatic Cancer Cells
- (2010) Chien-An Chen et al. PANCREATOLOGY
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- Construction and Expression of Specificity-Improved Single-Chain Variable Fragments against the Bioactive Naphthoquinone, Plumbagin
- (2009) Seiichi Sakamoto et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- A spectroscopic investigation into the interactions of 3′-O-carboxy esters of thymidine with bovine serum albumin
- (2009) Kalyan Sundar Ghosh et al. BIOPOLYMERS
- Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase- plasminogen activator
- (2009) Yuan-Wei Shih et al. HEPATOLOGY RESEARCH
- Inhibition of Lysine Acetyltransferase KAT3B/p300 Activity by a Naturally Occurring Hydroxynaphthoquinone, Plumbagin
- (2009) Kodihalli C. Ravindra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Apogossypol Derivatives as Pan-Active Inhibitors of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins
- (2009) Jun Wei et al. JOURNAL OF MEDICINAL CHEMISTRY
- Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells
- (2009) S. Nazeem et al. MUTAGENESIS
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- A frequent kinase domain mutation that changes the interaction between PI3K and the membrane
- (2009) D. Mandelker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Natural Naphthoquinone Plumbagin Exhibits Antiproliferative Activity and Disrupts the Microtubule Network through Tubulin Binding†
- (2008) Bipul R. Acharya et al. BIOCHEMISTRY
- Plumbagin, a Medicinal Plant–Derived Naphthoquinone, Is a Novel Inhibitor of the Growth and Invasion of Hormone-Refractory Prostate Cancer
- (2008) Moammir H. Aziz et al. CANCER RESEARCH
- Targeting STAT3 in cancer: how successful are we?
- (2008) Peibin Yue et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Akt as a therapeutic target in cancer
- (2008) Linda S Steelman et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Use of Akt Inhibitor and a Drug-resistant Mutant Validates a Critical Role for Protein Kinase B/Akt in the Insulin-dependent Regulation of Glucose and System A Amino Acid Uptake
- (2008) Charlotte J. Green et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-κB and Bcl-2
- (2008) Aamir Ahmad et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Plumbagin-induced Apoptosis in Human Prostate Cancer Cells is Associated with Modulation of Cellular Redox Status and Generation of Reactive Oxygen Species
- (2008) Anna A. Powolny et al. PHARMACEUTICAL RESEARCH
- Genotoxicity of plumbagin and its effects on catechol and NQNO-induced DNA damage in mouse lymphoma cells
- (2008) Jemal Demma et al. TOXICOLOGY IN VITRO
- Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells
- (2007) Clay C.C. Wang et al. CANCER LETTERS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started